StoneX Group’s GT Biopharma GTBP Stock Holding History

StoneX Group’s Portfolio GTBP Stock Details GTBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8.67K	Buy	23,258 +8,502	+58%	+$3.45K	﹤0.01%	1374
2026 Q1	$6.02K	Buy	+14,756	New	+$8.05K	﹤0.01%	875

Other funds holding GTBP

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

EFG

Everhart Financial Group Dublin, Ohio $1.56B AUM 34.29% 1-Year Est. Return

AAP

Arax Advisory Partners Denver, Colorado $15.1B AUM 27.93% 1-Year Est. Return

OWA

Opal Wealth Advisors Jericho, New York $463M AUM 20.47% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

4WM

49 Wealth Management Austin, Texas $524M AUM 16.59% 1-Year Est. Return

Alongside Austin, Texas $525M AUM

StoneX Group's GTBP Position: Q2 2026 in Review

StoneX Group increased its GT Biopharma (GTBP) stake by 58% in Q2 2026, buying an estimated $3.45K and bringing the position to 23,258 shares worth $8.67K. The position accounts for ﹤0.01% of the portfolio, ranked #1374.

StoneX Group first reported a position in GTBP in Q1 2026 and has held it in 2 quarters since. 59 funds tracked by Wall St. Rank hold GTBP as of Q2 2026.

StoneX Group held 23,258 shares of GT Biopharma worth $8.67K as of Q2 2026.
StoneX Group bought 8,502 GT Biopharma shares in Q2 2026, an estimated $3.45K.
GT Biopharma made up ﹤0.01% of StoneX Group's portfolio in Q2 2026, its #1374 holding.
StoneX Group first reported a position in GT Biopharma in Q1 2026 and has held it in 2 quarters since.
59 funds tracked by Wall St. Rank held GT Biopharma as of Q2 2026.

Based on StoneX Group's 13F filing for Q2 2026, filed 12 Aug 2026.